The Board of Directors of Baxter International Inc. (NYSE:BAX) today
declared a quarterly dividend of $0.45 per Baxter common share. The
dividend is payable on April 1, 2013 to shareholders of record as of
March 8, 2013.
Baxter continues to generate strong cash flow and has returned
significant value to shareholders in the form of dividends and share
repurchases. In 2012, Baxter returned approximately $2.3 billion to
shareholders through dividends totaling $800 million and share
repurchases of approximately $1.5 billion (or approximately 25 million
shares).
Baxter International Inc., through its subsidiaries, develops,
manufactures and markets products that save and sustain the lives of
people with hemophilia, immune disorders, infectious diseases, kidney
disease, trauma, and other chronic and acute medical conditions. As a
global, diversified healthcare company, Baxter applies a unique
combination of expertise in medical devices, pharmaceuticals and
biotechnology to create products that advance patient care worldwide.
This release includes forward-looking statements concerning the
company's dividend. The statements are based on assumptions about many
important factors, including the following, which could cause actual
results to differ materially from those in the forward-looking
statements: continued strength in the company’s financial position,
including cash flows; future decisions of the board of directors of the
company to continue payments to shareholders in the form of a dividend
on a quarterly or other basis relative to alternative uses of funds; and
other risks identified in the company's most recent filing on Form 10-K
and other SEC filings, all of which are available on the company's
website. The company does not undertake to update its forward-looking
statements.
